Thus, the molecular mechanism we discovered may apply to both IDH-wildtype and IDH-mutant glioblastomas [34], influencing SPARC production via either IRE1α or AKT/ENTPD5 might represent a worthwhile therapeutic option to pursue. This evidence concerns the gene SPARC and glioblastoma.